Clinical Trial Update: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CT053 in relapsed/refractory multiple myeloma (LUMMICAR STUDY 1) spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CT053

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN